- •MOG-IgG in serum denotes an emerging autoimmune CNS disorder.
- •We report a case of MOG-IgG demyelination with MS-phenotype.
- •Immunotherapies approved for MS may not be effective in this condition.
- •In our patient effective disease control could be achieved with alemtuzumab.
Immunoglobulin G (IgG) antibodies against myelin oligodendrocyte glycoprotein in serum denote an emerging autoimmune disorder of the central nervous system. Treatment trials have not been performed so far and anecdotal reports suggest that immunotherapies approved for multiple sclerosis (MS) may not be effective. We report favorable disease control with alemtuzumab, a CD52 depleting antibody approved for active MS, in a 34-year-old woman with the rarer condition of MOG-IgG disease with MS-phenotype. MOG-IgG in serum persisted over the entire observation period of almost five years. This case emphasizes that treatment responses may be distinct for different phenotypes of MOG-IgG associated disease.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?.Mult Scler Relat Disord. 2019; 33: 67-69
- Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults.Curr Opin Neurol. 2019; 32: 459-466
- Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.Clin Immunol. 2011; 138: 247-254
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.J Neuroinflammation. 2018; 15: 134
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.J Neuroinflammation. 2016; 13: 280
- Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.Brain. 2017; 140: 617-627
- Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.Neurol Neuroimmunol Neuroinflamm. 2015; 2: e163
- Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.Neurol Neuroimmunol Neuroinflamm. 2020; 7
- MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder.Mult Scler Relat Disord. 2018; 25: 66-72
- Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.J Neuroinflammation. 2017; 14: 208
- Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.J Neurol Neurosurg Psychiatry. 2018; 89: 127-137
- International multicenter examination of MOG antibody assays.Neurol Neuroimmunol Neuroinflamm. 2020; 7
- Immunological Aspects of Approved MS Therapeutics.Front Immunol. 2019; 10: 1564
- Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.Neurol Neuroimmunol Neuroinflamm. 2016; 3: e257
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173
- Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.J Clin Immunol. 2001; 21: 155-170
- Defining distinct features of anti-MOG antibody associated central nervous system demyelination.Ther Adv Neurol Disord. 2018; 111756286418762083
- Failure of alemtuzumab therapy to control MOG encephalomyelitis.Neurology. 2017; 89: 207-209
- Neurological update: MOG antibody disease.J Neurol. 2019; 266: 1280-1286
Published online: April 15, 2020
Accepted: April 6, 2020
Received in revised form: April 5, 2020
Received: March 20, 2020
© 2020 Elsevier B.V. All rights reserved.